Brought to you by 
Bristol signs new deal with Five Prime involving CSFR1 antibody
11 Oct 2021
Executive Summary
Replacing a deal signed in March 2014, Bristol-Myers Squibb Co. received exclusive global rights to develop and sell Five Prime Therapeutics Inc.'s Phase I colony stimulating Factor 1 receptor (CSF1R) inhibitor antibody FPA008 (cabiralizumab) for immuno-oncology indications. The agreement also includes all modifications, derivatives, fragments or variants of anti-CSFR1 antibodies.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Trial Collaborations
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bristol signs new deal with Five Prime involving CSFR1 antibody
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice